David Taus, Chief Executive Officer
Mr. Taus has over 30 years experience in the medical device, IVD, and biotech industry. He has a proven record in executive management and directing product development, sales, marketing, operations, and manufacturing in medical product regulated markets. He was the founder of Trend Scientific, an infectious disease immunodiagnostic company which was merged with Alexon Biomedical. He served as President of Alexon-Trend, Inc., which was an operating unit of Apogent Technologies. In these capacities he has developed and successfully introduced numerous medical diagnostic products. He received his B.A. in Biosciences from St. Mary’s University
Ernie Sumsion, Chief Operating Officer
Mr. Sumsion has a 25-year track record in management, operations and regulatory affairs in the medical device industry. He has successfully brought medical devices through the FDA approval process. While Senior Vice President, Vice President of Operations, Chief Operations Officer and Executive Vice President of Gull Laboratories, revenue there grew from $1.2 million to $17.9 million. As Vice President and Director of Operations at Alexon-Trend (Apogent Technologies), Mr. Sumsion achieved ISO9001:1994 certification for its operations. He received his M.B.A. from the University of Utah.
Roger Jensen, Chief Financial Officer
President of Centennial Capital Corporation, a financial advisory firm specializing in Mergers and Acquisitions, Corporate Finance and Reorganization, and Strategic Growth Planning. He has over 25 years senior management experience in a variety of industries including Life Science and has been engaged with DxNA since 2012. From 1997-2001 he served as Executive Vice President for Apogent Technologies where he had the lead role in creating and managing Apogent’s $200 million Microbiology Group. In this and other corporate capacities he has developed and successfully introduced numerous diagnostic products into both the clinical and research markets. He has earned an MBA and CPA having started his career with KPMG (formerly Peat, Marwick) in their business advisory practice. He brings to DxNA significant business, management and financial expertise.
Michael Wood, PhD., Senior Director Research and Development
Dr. Wood joined DxNA in December 2013 as Senior Director of Research and Development and brings with him over 20 years’ experience in the molecular diagnostics industry. Prior to joining DxNA Dr. Wood was Senior Director of Research and Development at GenturaDx, a company developing sample-to-answer PCR based tests on an integrated instrument platform, until its acquisition by Luminex Corp. in 2012. Previously, Dr. Wood was Program Director at GenMark Dx, where he directed the development of IVD and research use products for infectious disease, oncology, and SNP detection. Dr. Wood has been awarded 12 US patents and has authored over 25 publications. He received his D.Phil. degree from the University of York, UK and was a Post-Doctoral Research Fellow at the Massachusetts Institute of Technology.
Jim Maples, Director of Administration
Mr. James Maples has operated as Chief Financial Officer for DxNA LLC and other preceding related companies. He has lectured at Dixie State Collage on Entrepreneurship and at Utah State University has taught upper division Marketing. Mr. Maples has had a wide and varied career in commercial real estate as a broker and commercial real-estate development. He has been an owner and manager of several small businesses and has served as General Manager of a technical plastics manufacturing company and a Hologram manufacturing company. He received his B,S, in Production Management and his M.B.A. from Utah State University.
Todd Snowden, Director of Business Development
Todd Snowden joined DxNA in January 2014 following the acquisition by DxNA of PathoGene, a molecular diagnostic development company where Todd was President and CEO. Todd was brought in to PathoGene to raise initial funding, in-license technology, drive the development of the companies first molecular assays and to out-license these assays. Prior to PathoGene Todd was President and CEO of Ascent Business Advisors, a consulting firm focused on development and commercialization strategies for biotechnology and medical device companies, developing products, value propositions and strategies that deliver high margin revenue. In addition, Todd has 25 years of experience in the US and Europe in sales, business development, product management, sales and marketing management, and general business management roles primarily in medical diagnostics, medical laboratory services and medical device companies ranging in size from start-up to Fortune 500. Todd received his Bachelors Degree in Bioengineering from the Catholic University of America.